BioSpace News Archive

Globus Medical, Inc., a leading musculoskeletal solutions company, announced its financial results for the quarter ended September 30, 2023.

Rapid Micro Biosystems, Inc. announced that the Company will participate in the following investor conferences in New York, NY:

Apollo Medical Holdings, Inc. announced that it and its affiliated professional entity have entered into a definitive agreement to acquire assets relating to Community Family Care Medical Group IPA, Inc., including the CFC independent physician association, the CFC Health Plan and CFC’s management services organization entities.

Paragon 28, Inc., a leading medical device company exclusively focused on the foot and ankle orthopedic market, reported financial results for the quarter ended September 30, 2023 and reaffirmed its 2023 net revenue guidance.

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced financial results for the three and nine months ended September 30, 2023.

Outset Medical, Inc. (Nasdaq: OM) (“Outset” or the “Company”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the third quarter ended September 30, 2023.

KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”) today announced that it received U.S. Food and Drug Administration (FDA) clearance for use of the FREEDOM60® Infusion System with Hizentra® 50 mL prefilled syringes (PFS).

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the third quarter of 2023.

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported financial results for the third quarter ended September 30, 2023.

Aytu BioPharma, Inc. (the Company or “Aytu”) (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report financial results for its first quarter of fiscal year 2024 for the period ended September 30, 2023, after the market close on Tuesday, November 14, 2023.